Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 30;60(8):1240.
doi: 10.3390/medicina60081240.

Statins during Anticoagulation for Emergency Life-Threatening Venous Thromboembolism: A Review

Carmine Siniscalchi  1   2 , Egidio Imbalzano  3 , Tiziana Meschi  1 , Andrea Ticinesi  1 , Beatrice Prati  1 , Manuela Basaglia  1 , Giuseppe Camporese  4 , Alessandro Perrella  5 , Andreev Viorica  1 , Elisa Eletto  1 , Vincenzo Russo  6 , Paolo Simioni  4
Affiliations
Review

Statins during Anticoagulation for Emergency Life-Threatening Venous Thromboembolism: A Review

Carmine Siniscalchi et al. Medicina (Kaunas). .

Abstract

Venous thromboembolism (VTE) is the leading cause of morbidity and death worldwide, after cancer and cardiovascular diseases. VTE is defined to include pulmonary embolism (PE) and/or deep vein thrombosis (DVT). Approximately 25% of PE patients experience sudden death as an initial symptom of VTE, and between 10% and 30% of patients die within the first month after diagnosis. Currently, the only drugs approved for the treatment of both acute and chronic VTE are vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs). However, their effectiveness is limited due to their associated risk of bleeding. Ideally, therapy should be able to treat VTE and limit the risk of VTE recurrence without increasing the risk of bleeding. Several studies have shown that the use of statins during anticoagulation for VTE reduces the risk of death and VTE recurrence. However, to date, there are conflicting data on the impact of statins during anticoagulation for VTE. A biological protective function of statins during anticoagulation has also been reported. Statins affect D-dimer levels; tissue factor (TF) gene expression; and VIII, VII, and Von Willebrand clotting factors-the major clotting factors they are able to affect. However, the usefulness of statins for the treatment and prevention of VTE is currently under debate, and they should not be substituted for guideline-recommended VTE prophylaxis or anticoagulation treatment. In this review of the literature, we illustrate the advances on this topic, including data on the role of statins in primary VTE prevention and secondary VTE prevention, related biological mechanisms, the risk of bleeding during their use, and their ability to reduce the risk of death.

Keywords: blood clotting; deep vein thrombosis; pulmonary embolism; statin; venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Influence of statins on different clotting factors. The main clotting factors inhibited by statins are shown in red.
See this image and copyright information in PMC

References

    1. Smith S.B., Geske J.B., Maguire J.M., Zane N.A., Carter R.E., Morgenthaler T.I. Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest. 2010;137:1382–1390. doi: 10.1378/chest.09-0959. - DOI - PMC - PubMed
    1. Beckman M.G., Hooper W.C., Critchley S.E., Ortel T.L. Venous thromboembolism: A public health concern. Am. J. Prev. Med. 2010;38((Suppl. S4)):S495–S501. doi: 10.1016/j.amepre.2009.12.017. - DOI - PubMed
    1. Agnelli G., Buller H.R., Cohen A., Curto M., Gallus A.S., Johnson M., Porcari A., Raskob G.E., Weitz J.I., AMPLIFY-EXT Investigators Apixaban for extended treatment of venous thromboembolism. N. Engl. J. Med. 2013;368:699–708. doi: 10.1056/NEJMoa1207541. - DOI - PubMed
    1. Schulman S., Kearon C., Kakkar A.K., Schellong S., Eriksson H., Baanstra D., Kvamme A.M., Friedman J., Mismetti P., Goldhaber S.Z., et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N. Engl. J. Med. 2013;368:709–718. doi: 10.1056/NEJMoa1113697. - DOI - PubMed
    1. Becattini C., Agnelli G., Schenone A., Eichinger S., Bucherini E., Silingardi M., Bianchi M., Moia M., Ageno W., Vandelli M.R., et al. Aspirin for preventing the recurrence of venous thromboembolism. N. Engl. J. Med. 2012;366:1959–1967. doi: 10.1056/NEJMoa1114238. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources